| Identification | More | [Name]
4-(Trifluoromethyl)-2'-biphenylcarboxylic acid | [CAS]
84392-17-6 | [Synonyms]
4'-(TRIFLUOROMETHYL)[1,1'-BIPHENYL]-2-CARBOXYLIC ACID
4'-(TRIFLUOROMETHYL)-2-BIPHENYLCARBOXYLIC ACID
4-(TRIFLUOROMETHYL)-2'-BIPHENYLCARBOXYLIC ACID
4'-TRIFLUOROMETHYL-BIPHENYL-2-CARBOXYLIC ACID
AKOS BAR-0249
RARECHEM AL BO 1014
xenalipin
Xenalipine
2,2-DIFLUORO-3,3-BENZODIOXOLE-5-SULFONYLCHLORIDE
BW-207U | [Molecular Formula]
C14H9F3O2 | [MDL Number]
MFCD00075353 | [Molecular Weight]
266.22 | [MOL File]
84392-17-6.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection . | [WGK Germany ]
3
| [Hazard Note ]
Irritant | [HazardClass ]
IRRITANT | [HS Code ]
29162090 |
| Hazard Information | Back Directory | [Chemical Properties]
White solid | [Originator]
Xenalipin ,Wellcome (GSK) | [Uses]
4''-(Trifluoromethyl)-2-biphenylcarboxylic Acid, is a novel compound which has been found to be effective hypolipidemic agent in animal species. It is also an intermediate in the synthesis of various pharmaceutical compounds, such as Cannabinol (C175350). | [Uses]
Hypolipidemic. | [Manufacturing Process]
a). Preparation of 2-(4,4-dimethyl-2-oxazolin-2-yl)-4'-trifluoromethylbiphenyl:
A mechanically stirred solution of magnesium turnings (5.1 g, 0.21 mole)
Mallinckrodt, for Grignards reaction, and 2-(2-methoxyphenyl)-4,4-dimethyl-
2-oxazoline (41 g, 0.2 mole) in 50 mL dry tetrahydrofuran under nitrogen was
prepared. To this was added a crystal of iodine, 1 mL of dibromethane and 2
mL of neat p-bromotrifluoromethylbenzene to initiate the Grignard reaction.
Following initiation of the reaction, the remainder of the p-
bromotrifluoromethylbenzene (50 g, 0.22 mole total) in 100mL dry
tetrahydrofuran was added dropwise at a rate sufficient to maintain the
reaction at gentle reflux. The addition took 1 hour. At the end of the addition
period, the reaction mixture was heated to reflux for 3 hours. The reaction
mixture was then cooled to room temperature and 10 mL water was added
dropwise to coagulate the salts. The tetrahydrofuran was decanted and the
remaining solids were slurried twice with 300 mL ethyl ether and twice with
300 mL dichloromethane. Each organic extract was decanted from the solids
in turn and combined and evaporated under reduced pressure to an oil.
This oil was redissolved in 300 mL dichloromethane, washed once with 100
mL water and once with 10 mL saturated sodium chloride solution, dried and
concentrated under reduced pressure. The resulting residue was distilled
under reduced pressure (0.040 mm, 95.degree.) to yield 2-(4,4-dimethyl-2-
oxazoline-2-yl)-4'-trifluoromethylbiphenyl, yield 33%. A sample was
recrystallized from 30-60°C petroleum ether (melting point 50-51°C).
b). Preparation of 4'-(trifluoromethyl)-2-biphenylcarboxylic acid:
A solution of 2-(4,4-dimethyl-2-oxazolin-2-yl)-4'-trifluoromethylbiphenyl (3.5
g, 0.011 mole) in 60 mL 6 N hydrochloric acid was stirred at vigorous reflux
for 2 hr. The reaction mixture was then cooled to room temperature and
extracted with methylene chloride. The organic extracts were dried and
concentrated under reduced pressure to yield a solid. Recrystallisation from
ethyl ether/pentane afforded 4'-(trifluoromethyl)-2-biphenyl carboxylic acid,
yield 86% (melting point 167-169°C). | [Therapeutic Function]
Antihyperlipidemic | [General Description]
4′-(Trifluoromethyl)-2-biphenylcarboxylic acid (xenalipin) has been tested as an effective hypolipidemic agent in animal species. It has been shown to cause significant reduction in serum cholesterol and triglyceride levels in animal models and would be beneficial in therapy for hyperlipidemia. Synthesis of 4′-(trifluoromethyl)-2-biphenylcarboxylic acid (xenalipin) has been reported. Xenalipin has been synthesized in the [14C]-labelled form, with specific activity 21.0mCi/mmol, which is suitable for the metabolism and distribution studies in animals. |
|
|